Trade Sumitomo Dainippon Pharma Co., Ltd. - 4506
Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.Latest shares articles

GameStop stock forecast: debt exchange, Q2 profit
GameStop is a US video-game retailer. In Q2 fiscal 2026, net sales fell to $790.2m, while operating income rose to $160.2m. Explore third-party GME price targets and technical analysis. Past performance is not a reliable indicator of future results.
14:06, 7 October 2026

Freenet stock forecast: revenue rises, EBITDA falls
Freenet reported first-half 2026 revenue of €1,512.9 million, up 24.7% year on year, while adjusted EBITDA fell 5.9% to €242.2 million and 2026 guidance was maintained. Explore third-party FNTN price targets and technicals. Past performance is not a reliable indicator of future results.
12:41, 7 October 2026

Hims & Hers Health stock forecast: FDA GLP-1 warning
Hims & Hers Health is a US telehealth company. In August 2026, the FDA issued a warning concerning unapproved compounded GLP-1 weight-loss drugs. Explore third-party HIMS price targets and technical analysis. Past performance is not a reliable indicator of future results.
12:18, 7 October 2026

Arm Holdings stock forecast: Haas flags AI demand
Arm Holdings is a UK-based semiconductor company. Chief executive Rene Haas said AI and data-centre demand showed no signs of slowing. Explore third-party ARM price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:43, 6 October 2026